News Daily News AI-Supported Coaching Shows Promise for Improving Glycemic Control L.A. McKeown August 25, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Conference News AHA 2023 DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI Shelley Wood November 11, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Daily News Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs Michael O'Riordan March 25, 2016
News Daily News Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina Michael O'Riordan March 25, 2016